2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024
Open accessThe DOI matches its Crossref record; 240 of the 240 references it cites were found in a registry or an index; 152 of the 254 sources its claims cite were checked for support.
Abstract
The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
CoChat Summary
TL;DR
This ADA Standards of Care chapter provides updated recommendations for diagnosing and classifying diabetes, prediabetes, and related forms, including diagnostic thresholds, screening intervals, and classification categories. It emphasizes confirmatory testing, A1C limitations, risk-based screening, and special populations such as type 1 diabetes, gestational diabetes mellitus (GDM), cystic fibrosis–related diabetes (CFRD), posttransplantation diabetes mellitus (PTDM), pancreatic diabetes, and monogenic diabetes.
Key findings
- Diabetes diagnostic criteria: A1C ≥6.5% (≥48 mmol/mol), FPG ≥126 mg/dL (≥7.0 mmol/L), 2-h PG ≥200 mg/dL (≥11.1 mmol/L) during 75-g OGTT, or random plasma glucose ≥200 mg/dL (≥11.1 mmol/L) with classic hyperglycemic symptoms/crisis; absent unequivocal hyperglycemia, diagnosis requires two abnormal results. Prediabetes is defined by A1C 5.7–6.4% (39–47 mmol/mol), FPG 100–125 mg/dL (5.6–6.9 mmol/L; IFG), or 2-h PG 140–199 mg/dL (7.8–11.0 mmol/L; IGT).
- Classification includes type 1 diabetes (5–10% of diabetes), type 2 diabetes (90–95%), specific types due to other causes, and GDM. Misdiagnosis is common and can occur in ~40% of adults with new type 1 diabetes; type 1 diabetes staging shows ~44% 5-year risk of symptomatic disease at stage 1 and ~60% risk by 2 years and ~75% within 5 years at stage 2.
- Screening: begin at age 35 years for all adults; consider earlier in adults with overweight/obesity plus one or more risk factors; repeat at minimum 3-year intervals if normal. In children/adolescents, consider risk-based screening after puberty or age 10 years, whichever is earlier, with overweight/obesity plus risk factors.
- Special populations: GDM screening at 24–28 weeks; one-step IADPSG criteria increase GDM diagnosis (e.g., 11.5% vs 4.9% in a 2021 USPSTF review) without demonstrated improved health outcomes. CFRD occurs in about 20% of adolescents and 40–50% of adults with cystic fibrosis; annual OGTT screening begins by age 10, and A1C is not recommended for screening due to low sensitivity. PTDM diagnosis is best made once stable on immunosuppression, usually at least 45 days after transplantation, with OGTT preferred. Monogenic diabetes accounts for <5% of diabetes; 80–85% of neonatal diabetes cases have a monogenic cause, and 30–50% of KATP-related neonatal diabetes improves with high-dose oral sulfonylureas.
Methods
- Design: ADA Standards of Care clinical practice guideline/consensus recommendations, updated annually by the ADA Professional Practice Committee, an interprofessional expert committee.
- Data/sample: No primary study sample; the chapter synthesizes published evidence and expert consensus. It references an ADA evidence-grading system (A/B/C/E) detailed in the Introduction and Methodology.
- Main analysis: Narrative synthesis of diagnostic, classification, and screening evidence with graded recommendations; no meta-analysis or primary data collection is reported in this chapter.
Limitations
- Stated evidence gaps include insufficient evidence for continuous glucose monitoring (CGM) for screening/diagnosis of prediabetes or diabetes; unknown optimal screening interval; uncertain benefit of treating early abnormal glucose metabolism; lack of randomized controlled trials for treating versus not treating GDM diagnosed by IADPSG but not Carpenter-Coustan criteria; and limited data on how treating maternal hyperglycemia affects offspring metabolic outcomes.
- Stated classification/diagnostic limitations include common misdiagnosis (e.g., ~40% of adults with new type 1 diabetes), poorly understood type 2 diabetes genetics, inadequate genetic data in diverse populations, and A1C unreliability in conditions such as hemoglobin variants, pregnancy, glucose-6-phosphate dehydrogenase deficiency, HIV, hemodialysis, recent blood loss/transfusion, or erythropoietin therapy.
- Evident from the text: this is a consensus guideline rather than a primary systematic review or meta-analysis; recommendations are graded A/B/C/E, with some based on expert consensus (E), and many cited studies are observational/cohort rather than randomized trials.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 2.1 Flowchart for investigation of suspected type 1 diabetes in newly diagnosed adults, based on data from White European populations. 1 No single clinical feature con fi rms type 1 diabetes in isolation. 2 Glutamic acid decarboxylase (GAD) should be the primary antibody measured and, if negative, should be followed by islet tyrosine phosphatase 2 (IA-2) and/or zinc transporter 8 (ZnT8) where these tests are available. In individuals who have not been treated with insulin, antibodies against insulin may also be useful. In those diagnosed at < 35 years of age who have no clinical features of type 2 diabetes or monogenic diabetes, a negative result does not change the diagnosis of type 1 diabetes, since 5 -10% of people with type 1 diabetes do not have antibodies. 3 Monogenic diabetes is suggested by the presence of one or more of the following features: A1C < 58 mmol/mol ( < 7.5%) at diagnosis, one parent with diabetes, features of a speci fi c monogenic cause (e.g., renal cysts, partial lipodystrophy, maternally inherited deafness, and severe insulin resistance in the absence of obesity), and monogenic diabetes prediction model probability > 5% (diabetesgenes.org/exeter-diabetes-app/ModyCalculator). 4 A C-peptide test is only indicated in people receiving insulin treatment. A random sample (with concurrent glucose) within 5 h of eating can replace a formal C-peptide stimulation test in the context of classi fi cation. If the result is $ 600 pmol/L ( $ 1.8 ng/mL), the circumstances of testing do not matter. If the result is < 600 pmol/L ( < 1.8 ng/mL) and the concurrent glucose is < 4 mmol/L ( < 70 mg/dL) or the person may have been fasting, consider repeating the test. Results showing very low levels (e.g., < 80 pmol/L [ < 0.24 ng/mL]) do not need to be repeated. Where a person is insulin treated, C-peptide must be measured prior to insulin discontinuation to exclude severe insulin de fi ciency. Do not test C-peptide within 2 weeks of a hyperglycemic emergency. 5 Features of type 2 diabetes include increased BMI ( $ 25 kg/m 2 ), absence of weight loss, absence of ketoacidosis, and less marked hyperglycemia. Less discriminatory features include non-White ethnicity, family history, longer duration and milder severity of symptoms prior to presentation, features of the metabolic syndrome, and absence of a family history of autoimmunity. 6 If genetic testing does not con fi rm monogenic diabetes, the classi fi cation is unclear and a clinical decision should be made about treatment. 7 Type 2 diabetes should be strongly considered in older individuals. In some cases, investigation for pancreatic or other types of diabetes may be appropriate. 8 A person with possible type 1 diabetes who is not treated with insulin will require careful monitoring and education so that insulin can be rapidly initiated in the event of glycemic deterioration. 9 C-peptide values 200 -600 pmol/L (0.6 -1.8 ng/mL) are usually consistent with type 1 diabetes or maturity-onset diabetes of the young but may occur in insulin-treated type 2 diabetes, particularly in people with normal or low BMI or after long duration. Reprinted and adapted from Holt et al. (36).](https://figures.cochat.ai/paper-figures/7be96ed282694b1c85997763e16ae474/2-diagnosis-and-classification-of-diabetes-i-standards-of-care-in-diabetes2024-i-figure-1.png)

Verification
Claims the paper makes
99 Valid · 9 Not valid · 35 Not checked · 32 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“However , in 2003 the ADA adopted the new range of 100 -125 mg/dL (5.6 -6.9 mmol/L) to better de fi ne IFG so that the population risk of developing diabetes with IFG would be similar to that with IGT (11).”
What the sources say
- Disputedcites [11] Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, 2003, Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, Diabetes Care sourceExperimental — accuracy not yet measured
In “The new criteria” (p. 8), the committee defines IFG as fasting plasma glucose of 110 to <126 mg/dL, not 100–125 mg/dL. The paper describes both IFG and IGT as risk factors for future diabetes, but it does not say the lower IFG threshold was adopted to make their population risks similar. (LLM, conf=0.91)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In most cases, such stressor steroidinduced hyperglycemia resolves by the time of discharge (142,143).”
What the sources say
- Partly supportedcites [142] Thomas, 2000, Early peri-operative hyperglycaemia and renal allograft rejection in patients without diabetes, BMC Nephrol sourceExperimental — accuracy not yet measured
The Results (Hyperglycaemia; page unavailable) show that mean glucose fell from immediately after surgery to the morning of day 2. The Discussion (page unavailable) describes steroid exposure and postoperative hyperglycaemia, but the paper does not report whether most patients’ hyperglycaemia resolved by discharge. (LLM, conf=0.82)
- Disputedcites [143] Chakkera, 2009, Hyperglycemia during the immediate period after kidney transplantation, Clin J Am Soc Nephrol sourceExperimental — accuracy not yet measured
The Abstract (Results) says hyperglycemia was sustained throughout hospitalization and that 66% of patients without pretransplantation diabetes required insulin at discharge. The Discussion says the authors did not know what proportion would ultimately recover, rather than finding that most cases resolved by discharge. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Because periodontal disease is associated with diabetes, the utility of screening in a dental setting and referral to primary care as a means to improve the diagnosis of prediabetes and diabetes has been explored (108 -110)”
What the sources say
- Not checked — no full text of the sourcecites [108] Lalla, 2013, Dental findings and identification of undiagnosed hyperglycemia, J Dent Res source
- Not checked — no full text of the sourcecites [109] Lalla, 2011, Identification of unrecognized diabetes and pre-diabetes in a dental setting, J Dent Res source
- Supportedcites [110] Herman, 2015, Screening for prediabetes and type 2 diabetes in dental offices, J Public Health Dent source
The Discussion (page unavailable) describes periodontal disease and its sequelae as risk factors for dysglycemia, supporting the general association claimed. The paper’s own Results (page unavailable) found no association between clinical evidence of periodontitis and dysglycemia in its study sample, so it should not be cited as demonstrating that association in this cohort. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In a community-based study of African American and non-Hispanic White adults without diabetes, baseline A1C was a stronger predictor of subsequent diabetes and cardiovascular events than fasting glucose (82).”
What the sources say
- Partly supportedcites [82] Selvin, 2010, Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults, N Engl J Med sourceExperimental — accuracy not yet measured
The Abstract Conclusions state that glycated hemoglobin was more strongly associated than fasting glucose with cardiovascular disease risk, but only similarly associated with diabetes risk. The study population was community-based and included Black and White adults without diabetes. Page numbers are not provided in our copy. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“The epidemiologic studies that formed the basis for recommending A1C to diagnose diabetes included only adult populations (112).”
What the sources say
- Could not verifycites [112] Cowie, 2010, Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988-2006, Diabetes Care sourceExperimental — accuracy not yet measured
The introductory discussion (page unavailable) says an international expert committee recommended A1C for diagnosis, but does not give the ages of participants in the epidemiologic studies behind that recommendation. The Research Design and Methods section (page unavailable) includes participants aged 12 and older in this paper’s own analysis; that does not establish the ages in the studies the committee relied on. Searches for adult-only evidence and pediatric populations did not resolve the claim. (LLM, conf=0.73)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
74 more claims · 46 with their cited sources checked
Create a free account to see all 175 claims and to verify the 3 references still open.
- Probably not a substantial claim. 29
- It may state two separate claims as one. 75
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HbA1c can be affected by some non-glycaemic factors, including anaemia due to iron deficiency or malaria, specific haemoglobin variants (eg, HbS and HbF), other haemoglobinopathies, polycythaemia due to living in high altitude, liver and kidney diseases, HIV, and specific drugs such as antiretroviral therapy for HIV.”
From Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants (2024) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many clinical guidelines recommend using a second confirmatory test for diabetes diagnosis and initiating treatment,6,21–23 although there is variation in this guidance.”
From Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants (2024) · cites this paper as [21]
Experimental — accuracy not yet measured
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,338
IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045
Cho, N. H., Shaw, J. E., Karuranga, S., Huang, Y., da Rocha Fernandes, J. D., Ohlrogge, A. W., & Malanda, B. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.02.023 · Cited by 7,283
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1183 · Cited by 6,220
Diagnosis and classification of diabetes mellitus
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s081 · Cited by 5,974
Hyperglycemia and adverse pregnancy outcomes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707943 · Cited by 5,563
Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance.
National Diabetes Data Group (1979) · Diabetes · doi:10.2337/diab.28.12.1039 · Cited by 4,909
International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes
The International Expert Committee (2009) · Diabetes Care · doi:10.2337/dc09-9033 · Cited by 3,185
Research works printed but not linked: 1
- International Diabetes Federation . IDF Diabetes Atlas, 10th edition. Brussels, Belgium, International Diabetes Federation, 2021. Accessed 26 September 2023. Available from https://www.diabetesatlas.org/atlas/tenth-edition/
Cited by
Martin, S. S., Aday, A. W., Allen, N. B., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Bansal, N., Beaton, A. Z., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001303 · Cited by 1,080
Zhou, B., Rayner, A. W., Gregg, E. W., Sheffer, K. E., Carrillo-Larco, R. M., Bennett, J. E., Shaw, J. E., Paciorek, C. J., Singleton, R. K., Barradas Pires, A., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)02317-1 · Cited by 1,013
Raverdy, V., Tavaglione, F., Chatelain, E., Lassailly, G., De Vincentis, A., Vespasiani-Gentilucci, U., Qadri, S. F., Caiazzo, R., Verkindt, H., Saponaro, C., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03283-1 · Cited by 169
“…status was defined at baseline on the basis of a previous history of diabetes, use of antidiabetic medications, fasting plasma glucose ≥126 mg dl −1 (7.0 mmol l −1 ) and/or 2 h plasma glucose ≥200 mg dl −1 (11.1 mmol l −1 ) during oral glucose tolerance test, and/or HbA1c ≥6.5% (48 mmol l −1 ) 41 .”
InfluentialHou, X.-Z., Lv, Y., Li, Y., Wu, Q., Lv, Q., Yang, Y.-T., Li, L., Ye, X., Yang, C.-Y., Wang, M.-S., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02173-7 · Cited by 170
Haller, M. J., Bell, K. J., Besser, R. E. J., Casteels, K., Couper, J. J., Craig, M. E., Elding Larsson, H., Jacobsen, L., Lange, K., Oron, T., et al. (2024) · Hormone Research in Paediatrics · doi:10.1159/000543035 · Cited by 151
“Notably, the 2024 ADA Standards of care include HbA1c of 5.7 – 6.4% (39 – 47 mmol/mol) or ≥ 10% increase in HbA1c as diagnostic of Stage 2 T1D [87].”
InfluentialDiabetes in China: epidemiology, pathophysiology and multi-omics
Jia, W., Chan, J. C. N., Wong, T. Y., & Fisher, E. B. (2025) · Nature Metabolism · doi:10.1038/s42255-024-01190-w · Cited by 115
Wu, F., Wang, Y., Li, Y., Shi, L., Lü, Y., Ren, Y., van der Mei, H. C., & Liu, Y. (2025) · ACS Nano · doi:10.1021/acsnano.4c12348 · Cited by 93
Kahn, S. E., Deanfield, J. E., Jeppesen, O. K., Emerson, S. S., Boesgaard, T. W., Colhoun, H. M., Kushner, R. F., Lingvay, I., Burguera, B. G., Gajos, G., et al. (2024) · Diabetes Care · doi:10.2337/dc24-0491 · Cited by 110
Self-citationMitochondrial Dysfunction, Oxidative Stress, and Inter-Organ Miscommunications in T2D Progression
Veluthakal, R., Esparza, D., Hoolachan, J. M., Balakrishnan, R., Ahn, M., Oh, E., Jayasena, C. S., & Thurmond, D. C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031504 · Cited by 99
“About 90–95% of all diabetes cases worldwide are composed of T2D cases [2,3].”
BackgroundDiabetes and its complications: molecular mechanisms, prevention and treatment
Zhao, L., Yuan, J., Yang, Q., Ma, J., Yang, F., Zou, Y., Liu, K., & Liu, F. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02401-w · Cited by 80
Phillip, M., Achenbach, P., Addala, A., Albanese-O’Neill, A., Battelino, T., Bell, K. J., Besser, R. E. J., Bonifacio, E., Colhoun, H. M., Couper, J. J., et al. (2024) · Diabetes Care · doi:10.2337/dci24-0042 · Cited by 79
Self-citationRomeo, S., Vidal‐Puig, A., Husain, M., Ahima, R. S., Arca, M., Bhatt, D. L., Diehl, A. M., Fontana, L., Foo, R., Frühbeck, G., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf314 · Cited by 108
Liao, J., Wang, L., Duan, L., Gong, F., Zhu, H., Pan, H., & Yang, H. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02570-y · Cited by 97
“Prediabetes was defined as impaired fasting glucose(IFG) between 100 and 125 mg/dL, or aberrant HbA1c (5.7-6.4%), or raising 2 h-OGTT ranged from 7.8 to 11.0mmol/L(IGT, impaired glucose tolerance), both of two conditions or self-reported prediabetes status [25].”
InfluentialDong, B., Chen, Y., Yang, X., Chen, Z., Zhang, H., Gao, Y., Zhao, E., & Zhang, C. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02729-1 · Cited by 98
“Diabetes was defined as a self-reported diagnosis by a physician, use of hypoglycemic drugs, FBG ≥ 7.0 mmol/L (126 mg/dL), and/or an HbA1c level ≥ 6.5% at baseline [23].”
InfluentialISPAD Clinical Practice Consensus Guidelines 2024: Type 2 Diabetes in Children and Adolescents
SHAH, A. S., Pérez, M. B., CHANG, N. T., Fu, J., Hannon, T. S., Kelsey, M. M., Peña, A. S., Pinhas‐Hamiel, O., Urakami, T., Wicklow, B. A., et al. (2024) · Hormone Research in Paediatrics · doi:10.1159/000543033 · Cited by 97
“IGT and impaired fasting glucose are intermediate stages in the T2D natural history transition from normal glucose homeostasis to overt hyperglycemia [32].”
Phillip, M., Achenbach, P., Addala, A., Albanese-O’Neill, A., Battelino, T., Bell, K. J., Besser, R. E. J., Bonifacio, E. E., Colhoun, H. M., Couper, J., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06205-5 · Cited by 136
“These are often considered ‘biochemical autoantibodies’ and are the screening targets recommended by the most-recent ADA Standards of Care [25].”
BackgroundSelf-citationSantulli, G., Visco, V., Varzideh, F., Guerra, G., Kansakar, U., Gasperi, M., Marro, A., Wilson, S. M., Ferrante, M. N. V., Pansini, A., et al. (2024) · Hypertension · doi:10.1161/hypertensionaha.124.23087 · Cited by 69
Wang, B., Li, L., Tang, Y., & Ran, X. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02724-6 · Cited by 79
“Diabetes mellitus was diagnosed based on self-reported diabetes history, use of antidiabetic medications, FPG ≥ 7.0 mmol/L, or HbA1c levels ≥ 6.5% [21].”
InfluentialGilbert, O., Gulati, M., Gluckman, T. J., Kittleson, M. M., Rikhi, R., Saseen, J. J., & Tchang, B. G. (2025) · JACC · doi:10.1016/j.jacc.2025.05.024 · Cited by 65
Lingvay, I., Deanfield, J. E., Kahn, S. E., Weeke, P. E., Toplak, H., Scirica, B. M., Rydén, L., Rathor, N., Plutzky, J., Morales, C., et al. (2024) · Diabetes Care · doi:10.2337/dc24-0764 · Cited by 84
Self-citationOrtíz, A., Guerra, J. M. A., Chan, J. C. N., Jha, V., Kramer, H., Nicholas, S. B., Pavkov, M. E., Wanner, C., Wong, L. P., Cheung, M., et al. (2025) · Kidney International · doi:10.1016/j.kint.2025.04.005 · Cited by 91
Self-citationGlucocorticoid-Induced Hyperglycemia: A Neglected Problem
Cho, J.-H., & Suh, S. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.1951 · Cited by 63
“It is important to recognize that HbA1c has diagnostic limitations due to factors that alter red blood cell lifespan [74].”
BackgroundMethodResultInfluentialHu, S., Ji, W., Zhang, Y., Zhu, W., Sun, H., & Sun, Y. (2025) · BMC Public Health · doi:10.1186/s12889-025-21404-4 · Cited by 90
Application of Chatbots to Help Patients Self-Manage Diabetes: Systematic Review and Meta-Analysis
Wu, Y., Zhang, J., Ge, P., Duan, T., Zhou, J., Wu, Y., Zhang, Y.-P., Liu, S., Liu, X., Wan, E., et al. (2024) · Journal of Medical Internet Research · doi:10.2196/60380 · Cited by 84
“Therefore, the main control of diabetes mellitus is the blood glucose level [3].”
Resilience to diabetic retinopathy
Serikbaeva, A., Li, Y., Ma, S., Yi, D., & Kazlauskas, A. (2024) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101271 · Cited by 51
Advances in Nanomedicine for Precision Insulin Delivery
Caturano, A., Nilo, R., Nilo, D., Russo, V., Santonastaso, E., Galiero, R., Rinaldi, L., Monda, M., Sardu, C., Marfella, R., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17070945 · Cited by 56
“In this condition, glucose is both inadequately utilized as an energy source and excessively produced due to inappropriate gluconeogenesis and glycogenolysis, leading to hyperglycemia [1].”
BackgroundDeep phenotyping of health–disease continuum in the Human Phenotype Project
Reicher, L., Shilo, S., Godneva, A., Lutsker, G., Zahavi, L., Shoer, S., Krongauz, D. L., Rein, M., Kohn, S., Segev, T., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03790-9 · Cited by 61
“Another example is the progression of fasting glucose (FG) levels with age, a key diagnostic criterion for prediabetes and diabetes 21 , which increases every 10 years by 2.6 mg dl −1 in males and 2.5 mg dl −1 in females (Fig.”
InfluentialTrimarco, V., Izzo, R., Pacella, D., Manzi, M. V., Trama, U., Lembo, M., Piccinocchi, R., Gallo, P., Esposito, G., Morisco, C., et al. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111926 · Cited by 52
Crawford, A. L., & Laiteerapong, N. (2024) · Annals of Internal Medicine · doi:10.7326/aitc202406180 · Cited by 54
Chen, H. L., Wu, C.-W. G., Cao, L., Wang, R., Zhang, T. Y., & He, Z. (2024) · BMC Endocrine Disorders · doi:10.1186/s12902-024-01637-x · Cited by 61
“Evidence suggests that low-grade inflammation plays a crucial role in the pathogenesis of T2DM [26], and HbA1c, a commonly used laboratory marker for diagnosing T2DM, reflects the average blood glucose levels of the human body over three months, facilitating the monitoring of these levels [27].”
BackgroundMarco, M. D., Scilletta, S., Miano, N., Capuccio, S., Musmeci, M., Mauro, S. D., Filippello, A., Scamporrino, A., Bosco, G., Barbagallo, F. D. G., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112189 · Cited by 42
Continuous Glucose Monitoring for Prediabetes: What Are the Best Metrics?
Zahalka, S. J., Galindo, R. J., Shah, V. N., & Wang, C. C. L. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241242487 · Cited by 56
Type 3 diabetes and metabolic reprogramming of brain neurons: causes and therapeutic strategies
Meng, X., Zhang, H., Zhao, Z., Li, S., Zhang, X., Guo, R., Li, H., Yuan, Y., Li, W., Song, Q., et al. (2025) · Molecular Medicine · doi:10.1186/s10020-025-01101-z · Cited by 50
Dual α-amylase and α-glucosidase inhibitors: recent progress from natural and synthetic resources
Jha, R., Goyal, K., Mehan, S., & Singh, G. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108762 · Cited by 55
Cichosz, S. L., Kronborg, T., Laugesen, E., Hangaard, S., Fleischer, J., Hansen, T. K., Jensen, M. H., Poulsen, P. L., & Vestergaard, P. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0226 · Cited by 48
Tsitsou, S., Bali, T., Adamantou, M., Saridaki, A., Poulia, K., Karagiannakis, D. S., Papakonstantinou, E., & Cholongitas, Ε. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70044 · Cited by 44
“We defined type 2 diabetes and prediabetes according to the American Diabetes Association guidelines [24], stratified blood pressure (BP) based on the 2023 European Society of Cardiology guidelines [25], defined dyslipidaemia using the European Society of Cardiology guidelines [26] and identified…”
Zhou, Y., Chen, Y., Tang, Y., Zhang, S., Zhuang, Z., & Ni, Q. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01673-0 · Cited by 49
“Consequently, the 2024 ADA guidelines recommend that even individuals without risk factors and with normal weight should begin diabetes screening at age 35, effectively lowering the screening threshold for T2DM [14].”
Liu, J., Yi, X., Zhang, J., Yao, Y., Panichayupakaranant, P., & Chen, H. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16101343 · Cited by 43
“According to the guidelines from the United States, Europe, China, Japan, and other regions, diabetes is classified into four categories based on etiological evidence: type 1 diabetes mellitus (T1D), type 2 diabetes mellitus (T2DM), gestational diabetes, and special types of diabetes [9,10].”
MethodSantulli, G., Visco, V., Ciccarelli, M., Ferrante, M. N. V., Masi, P. D., Pansini, A., Virtuoso, N., Pirone, A., Guerra, G., Verri, V., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02218-x · Cited by 42
“Prediabetes is recognized as a precursor to diabetes, diagnosed with HbA1c values between 5.7 and 6.4% [14, 15], and is often accompanied by cardiovascular comorbidities, such as hypertension, thereby elevating the risk of pre-frailty and frailty [16, 17].”
InfluentialRole of Triglyceride-Glucose Index in Type 2 Diabetes Mellitus and Its Complications
Pan, Y., Zhao, M., Song, T., Tang, J., Kuang, M., Liu, H., & Zhong, S. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s478287 · Cited by 37
Gestational Diabetes: An Update 60 Years After O’Sullivan and Mahan
McIntyre, H. D., Kampmann, U., Dalsgaard Clausen, T., Laurie, J., & Ma, R. C. W. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae709 · Cited by 32
Lin, K., Ai, W., Zhai, C., Zhao, Y., Hu, H., Huang, D., Zhai, Q., Yan, Y., & Ge, J. (2024) · British Journal of Pharmacology · doi:10.1111/bph.17327 · Cited by 38
von Schwartzenberg, R. J., Arreola, E. V., Sandforth, A., Hanson, R. L., & Birkenfeld, A. L. (2024) · Diabetologia · doi:10.1007/s00125-024-06178-5 · Cited by 33
“%) but not meeting glycaemic criteria for type 2 diabetes [2]) have a lifetime risk of developing type 2 diabetes of 73%.”
BackgroundLai, X., & Chen, T. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1476336 · Cited by 33
Interaction between diabetes and osteoporosis: imbalance between inflammation and bone remodeling
Zhang, X. L., Xu, D., Zhang, R., Wang, H., & Yang, G. (2025) · Osteoporosis International · doi:10.1007/s00198-025-07636-5 · Cited by 50
“…example, the American Diabetes Association (ADA) and the International Osteoporosis Foundation (IOF) have identified type 2 diabetes as a clinical risk factor for fragility fractures, regardless of normal bone mineral density, and recommend adjusting fracture risk assessments accordingly [[3, 15].”
Rosselot, C., Li, Y., Wang, P., Alvarsson, A., Beliard, K., Lu, G., Kang, R. B., Li, R., Liu, H., Gillespie, V., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adg3456 · Cited by 37
“Even in first-world countries, 70% of people with diabetes fail to achieve targets for blood glucose control ( 5 – 7 ).”
BackgroundWang, B., Li, L., Tang, Y., Lin, T., Wu, J., Wang, G., & Ran, X. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02536-3 · Cited by 37
“…participants who met at least one of the following criteria: (1) a self-reported history of diabetes; (2) current use of antihyperglycemic medications or insulin therapy; (3) fasting plasma glucose (FPG) levels ≥ 7.0 mmol/L and/or HbA1c (glycosylated hemoglobin A1c) levels ≥ 6.5% at baseline [19].”
InfluentialBonifacio, E. E., & Ziegler, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16354 · Cited by 40
“8 A comparison of diagnostic criteria has revealed significant differences in the rates of progression to Stage 3 type 1 diabetes depending on the number and type of impaired values.”
Reframing prediabetes: A call for better risk stratification and intervention
Kim, S. H. (2024) · Journal of Internal Medicine · doi:10.1111/joim.13786 · Cited by 32
“Several organizations recommend universal screening for prediabetes or diabetes for all individuals beginning at the age of 35–40 years [23, 27] and selective screening for overweight/obese individuals identified by risk factors or validated risk calculators [28]. calculators have high predictive…”
BackgroundLee, H., Schwamm, L. H., Sansing, L. H., Kamel, H., de Havenon, A., Turner, A. C., Sheth, K. N., Krishnaswamy, S., Brandt, C., Zhao, H., et al. (2024) · npj Digital Medicine · doi:10.1038/s41746-024-01120-w · Cited by 34
Battelino, T., Lalic, N. M., Hussain, S., Ceriello, A., Majanović, S. K., Davies, S., Topsever, P., Heverly, J., Ulivi, F., Brady, K., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112111 · Cited by 36
Trimarco, V., Izzo, R., Jankauskas, S. S., Fordellone, M., Signoriello, G., Manzi, M. V., Lembo, M., Gallo, P., Esposito, G., Piccinocchi, R., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci183777 · Cited by 26
Ruggieri, E., Domenico, E. D., Locatelli, A. G., Isopo, F., Damanti, S., LORENZO, R. D., Milan, E., Musco, G., Rovere, P. Q., Cenci, S., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102550 · Cited by 29
Zhao, S., Wang, Z., Qing, P., Li, M., Liu, Q., Pang, X., Wang, K., Gao, X., Zhao, J., & Wu, Y. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02355-3 · Cited by 29
“The glucose metabolism state was diagnosed according to the latest American Diabetes Association (ADA) “Standards of Care in Diabetes”, taking into account FPG and HbA1c levels measured during hospitalization, while also considering self-reported prior diagnosis and medication [20].”
MethodYan, L., Zhou, Z., Wu, X., Qiu, Y., Liu, Z., Luo, L., Yang, Y., Lü, X., He, J., & Xia, W. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16179 · Cited by 28
Type 1 diabetes mellitus prevention: present and future
Henriques, F. L., Buckle, I., & Forbes, J. M. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01128-6 · Cited by 36
“Finally, stage 3 is reached when clinical disease manifests symptomatically as weight loss, polyuria, polydipsia, polyphagia and often ketoacidosis, fulfilling the current diagnostic criteria 14 .”
InfluentialBallena-Caicedo, J., Zuzunaga-Montoya, F. E., Loayza-Castro, J. A., Bustamante-Rodríguez, J. C., Vásquez-Romero, L. E. M., Tapia‐Limonchi, R., Carrillo, C. I. G. D., & Vera-Ponce, V. J. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1646258 · Cited by 45
Machine Learning Approach to Metabolomic Data Predicts Type 2 Diabetes Mellitus Incidence
Leiherer, A., Muendlein, A., Mink, S., MADER, A., Saely, C. H., Festa, A., Fraunberger, P., & Drexel, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105331 · Cited by 29
Triebl, Z., Bencze, B., Bányai, D., Rózsa, N. K., Hermann, P., & Végh, D. (2024) · BMC Oral Health · doi:10.1186/s12903-024-04516-y · Cited by 40
“…2 can develop on a multifactorial basis, mainly by an unhealthy lifestyle with the addition of bad diet and obesity; gestational diabetes develops and usually recedes within the gestational period; and lastly secondary diabetes that is either caused by certain medications or other illnesses [3].”
BackgroundChen, L., & Zhu, Y. (2024) · Current Diabetes Reports · doi:10.1007/s11892-024-01552-4 · Cited by 41
“…Groups (IADPSG) [1], the two-step approach is recommended by the National Institutes of Health (NIH) and American College of Obstetricians and Gynecologists ( AJOG) [2] and more commonly applied in the United States (U.S.)., and both approaches are endorsed by the American Diabetes Association [3].”
Phenome-wide associations of sleep characteristics in the Human Phenotype Project
Kohn, S., Diament, A., Godneva, A., Dhir, R., Weinberger, A., Reisner, Y., Rossman, H., & Segal, E. (2025) · Nature Medicine · doi:10.1038/s41591-024-03481-x · Cited by 36
“31) and 55.5% and 53.9% of the male population with diabetes, based on fasting glucose and HbA1c thresholds 32 , respectively, have a pAHI indicative of moderate OSA.”
InfluentialRecommendations for Screening and Monitoring the Stages of Type 1 Diabetes in the Immune Therapy Era
Moore, D. J., Leibel, N. I., Polonsky, W. H., & Rodriguez, H. (2024) · International Journal of General Medicine · doi:10.2147/ijgm.s438009 · Cited by 29
Zheng, C., Yin, J., Wu, L., Hu, Z., Zhang, Y., Cao, L., & Qu, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-78345-y · Cited by 35
“According to the American Diabetes Association recommendations and previous studies 16,17 , prediabetes was diagnosed if any of the following criteria were met: (1) 5.7% ≤ HbA1c ≤ 6.4%; (2) 5.6 mmol/L ≤ FBG ≤ 6.9 mmol/L; (3) 7.8 mmol/L ≤ OGTT ≤ 11.0 mmol/L. Diabetes was diagnosed if any of the…”
InfluentialFinerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial
Butt, J. H., Jhund, P. S., Henderson, A. D., Claggett, B. L., Desai, A. S., Viswanathan, P., Kolkhof, P., Schloemer, P., Amarante, F., Lam, C. S. P., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00309-7 · Cited by 39
Dai, W., & Albrecht, S. S. (2024) · Diabetes Care · doi:10.2337/dc24-0673 · Cited by 27
Rosenfeld, R. M., Grega, M. L., Karlsen, M. C., Dabrh, A. M. A., Aurora, R. N., Bonnet, J. P., Donnell, L., Fitzpatrick, S. L., Frates, E. P., Joy, E. A., et al. (2025) · American Journal of Lifestyle Medicine · doi:10.1177/15598276251325488 · Cited by 54
Desouter, A. K., Keymeulen, B., de Velde, U. V., Dalem, A. V., Lapauw, B., Block, C. E. M. D., Gillard, P., Seret, N., Balti, E. V., Vooren, E. R. V., et al. (2025) · Diabetes Care · doi:10.2337/dc24-2376 · Cited by 26
Wekalao, J. (2025) · Plasmonics · doi:10.1007/s11468-025-02815-w · Cited by 22
“Furthermore, they are not optimal for real-time, on-the-spot detection, nor are they well-suited for use in resource-constrained environments, where more straight-forward and cost-effective solutions would offer significant advantages[7].”
A systematic literature review on the burden of diabetic ketoacidosis in type 2 diabetes mellitus
Wysham, C., Bindal, A., Levrat‐Guillen, F., Kostadinova, D., & Poon, Y. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16282 · Cited by 32
Netayawijit, P., Chansanam, W., & Sorn-in, K. (2025) · Healthcare · doi:10.3390/healthcare13202588 · Cited by 43
Harnessing beta cell regeneration biology for diabetes therapy
Bourgeois, S., Coenen, S., Degroote, L., Willems, L., Mulders, A. V., Pierreux, J., Heremans, Y., Leu, N. D., & Staels, W. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.03.006 · Cited by 30
Diagnosis and Treatment of Hyperglycemia in Pregnancy
Mohan, S., & Egan, A. M. (2024) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2024.05.011 · Cited by 41
Wu, X., Tjahyo, A. S., Volchanskaya, V. S. B., Wong, L. H., Lai, X., Yong, Y. N., Osman, F., Tay, S. L., Govindharajulu, P., Ponnalagu, S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56084-6 · Cited by 35
“According to the American Diabetes Association (ADA) Guideline, prediabetic was de fi ned as having one or more of the following criteria: (1) fasting blood glucose >5.5 mmol/l and 7.0mmol/l, (2) oral glucose tolerance test (OGTT) level ≥ 7.8 mmol/l and ≤ 11.0mmol/l, (3) Hemoglobin A1c (HbA1c) level ≥ 5.7 and ≤ 6.4%.”
InfluentialLi, C., Zhao, S., Li, Y., He, S., Jian, W., Liu, Y., Cheng, Z., & Peng, H. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02555-x · Cited by 26
“Diabetes was defined as the presence of at least one of the following conditions: HbA1C% ≥ 6.5%; random blood glucose ≥ 11.1 mmol/L; fasting blood glucose ≥ 7.0 mmol/L; blood glucose ≥ 11.1 mmol/L 2 h after the oral glucose tolerance test [23].”
InfluentialDiabetes Management in Detention Facilities: A Statement of the American Diabetes Association
Lorber, D. L., ElSayed, N. A., Bannuru, R. R., Shah, V. N., Puisis, M., Crandall, J. P., Fech-Baughman, S., Wakeen, B., Dantone, J. J., Buskey, R. H., et al. (2024) · Diabetes Care · doi:10.2337/dci24-0015 · Cited by 25
Self-citationProgression From Presymptomatic to Clinical Type 1 Diabetes After COVID-19 Infection
Friedl, N., Sporreiter, M., Winkler, C., et al. (2024) · JAMA · doi:10.1001/jama.2024.11174 · Cited by 21
Bucciarelli, V., Moscucci, F., Dei, A., Coppi, F., Angeli, F., Pizzi, C., Renda, G., Nodari, S., Maffei, S., Montisci, R., et al. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102695 · Cited by 20
“…cases and is currently defined as diabetes diagnosed in the second or third trimester of pregnancy that was not clearly overt diabetes prior to gestation or other types of diabetes occurring throughout pregnancy, such as type 1 diabetes 65 ; ~90% of cases occurs in low-and middle-income countries.”
Neira, G., Becerril, S., Valentí, V., Moncada, R., Catalán, V., Gómez‐Ambrosi, J., Colina, I., Silva, C., Escalada, J., Frühbeck, G., et al. (2024) · Clinical Nutrition · doi:10.1016/j.clnu.2024.08.007 · Cited by 29
Susarla, S. M., Fiehn, O., Thiele, I., Ngo, A. L., Barupal, D. K., Chehab, R. F., Ferrara, A. M., & Zhu, Y. (2024) · BMC Medicine · doi:10.1186/s12916-024-03606-6 · Cited by 21
“…to fasting serum glucose concentrations given that glucose is routinely used in clinical practice for GDM early detection and risk assessment [26]; (2) Model 2: microbiome-derived metabolite panels at gestational weeks 10–13 and 16–19, respectively; and (3) Model 3: Models 1 and 2 combined.”
MethodOkawa, Y., Mitsuhashi, T., & Tsuda, T. (2025) · Biomedicines · doi:10.3390/biomedicines13020373 · Cited by 48
“%) during follow-up were treated as right-censored [22].”
Billings, L. K., Winne, L., Sharma, P., Valderas, E. G., Chivukula, K. K., & Kwan, A. Y. M. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-03849 · Cited by 28
Pecani, M., Andreozzi, P., Cangemi, R., Corica, B., Miglionico, M., Romiti, G. F., Stefanini, L., Raparelli, V., & Basili, S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14082750 · Cited by 29
“It arises from a non-autoimmune, progressive decline in adequate β -cell insulin secretion, typically occurring in the context of IR and MetS [47,48].”
Althuwayb, A. A., Rajan, M. S. M., Alzaid, M., et al. (2026) · Microchemical Journal · doi:10.1016/j.microc.2026.117030 · Cited by 20
Jang, G. Y., Chang, S. J., & Noh, J. H. (2024) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s448056 · Cited by 21
Chen, Y., Zhang, L., Xu, J., Xu, S., Li, Y., Sun, R., Huang, J., Peng, J., Gong, Z., Wang, J., et al. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.131876 · Cited by 21
Mora-Ortiz, M., & Rivas‐García, L. (2024) · Open Research Europe · doi:10.12688/openreseurope.18026.1 · Cited by 37
Haynes, A., Tully, A. S., Smith, G. J., Penno, M. A. S., Craig, M. E., Wentworth, J. M., Huynh, T., Colman, P. G., Soldatos, G., Anderson, A. J., et al. (2024) · Diabetes Care · doi:10.2337/dc24-0540 · Cited by 20
Peripheral Arterial Disease in Diabetic Foot: One Disease with Multiple Patterns
Meloni, M., & Vas, P. R. J. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14061987 · Cited by 31
“Dyslipidaemia, including total cholesterol LDL-C), triglycerides, and lipoprotein a, is closely atherosclerotic disease in several vascular managed by lower limb revascularisation recommended [94,98].”
InfluentialDiabetes mellitus polygenic risk scores: heterogeneity and clinical translation
Ortega, H. I., Udler, M. S., Gloyn, A. L., & Sharp, S. A. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01132-w · Cited by 32
“One notable example is INS , the gene that encodes insulin 30 .”
InfluentialLean diabetes is one end of the spectrum of type 2 diabetes and not a separate entity
Mohan, V., Pramodkumar, T. A., Deepa, M., Pradeepa, R., Ranjit Unnikrishnan, I., Routray, P., Tharunika, S., Lakshmi, N., Killivalavan, D., Ganesan, S., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112387 · Cited by 22
Jin, J., Yang, X., Feng, R., Ye, M.-L., Xu, H., Wang, J., Hu, J., Zuo, H., Lu, J., Song, J., et al. (2025) · The FASEB Journal · doi:10.1096/fj.202501579rr · Cited by 26
Prevalence of gestational diabetes mellitus in Pakistan: a systematic review and meta-analysis
Adnan, M., & Aasim, M. (2024) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-024-06290-9 · Cited by 42
“…Association of Diabetes and Pregnancy Study Groups (IADPSG) [6], the World Health Organization (WHO) [7], and the American Diabetes Association (ADA) [5] criteria, the cut-off values for the diagnosis of GDM are ≥ 92 mg/dl after fasting, ≥ 180 mg/dl after one-hour and ≥ 153 mg/dl after two-hour.”
BackgroundMethodGómez‐Ambrosi, J., Catalán, V., Ramírez, B., Salmón‐Gómez, L., Marugán-Pinos, R., Rodríguez, A., Becerril, S., Aguas‐Ayesa, M., Yárnoz‐Esquíroz, P., Olazarán, L., et al. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.02.027 · Cited by 22
Mayya, V., Kandala, R. N. V. P. S., Gurupur, V. P., King, C., Vu, G. T., & Wan, T. T. H. (2024) · Health Services Research and Managerial Epidemiology · doi:10.1177/23333928241275292 · Cited by 34
Deng, Y., Moniruzzaman, M., Rogers, B., Hu, L., Jagannathan, R., & Tamura, K. (2024) · Preventive Medicine Reports · doi:10.1016/j.pmedr.2024.102957 · Cited by 29
Harnessing Pharmacomultiomics for Precision Medicine in Diabetes: A Comprehensive Review
Dhieb, D., Mustafa, D. N., Hassiba, M., Alasmar, M., Elsayed, M. E. M., Musa, A., Zirie, M. A., & Bastaki, K. (2025) · Biomedicines · doi:10.3390/biomedicines13020447 · Cited by 28
Chia, A. W.-Y., Teo, W. L.-L., Acharyya, S., Munro, Y. L., & Dalan, R. (2025) · BMC Medicine · doi:10.1186/s12916-025-03873-x · Cited by 26
“These standardised indicators are clinical guidelines recommended by professional bodies [3–5] and are reference points to determine if treatment to target thresholds are met and whether a patient’s over-all condition is adequately managed [6].”
Liu, Z., Chen, W., Zhang, J., Huang, T., Hong, Y., Zhao, T.-J., Liu, M., Chen, Q.-H., Yang, Y.-Q., Wang, S.-Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-61883-y · Cited by 19
“Non-diabetes and T2DM were classi fi ed according to American Diabetes Association criteria 44 .”
Efeoğlu, Ç., Sadak, S., Şahi̇n, E., et al. (2025) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2025.130417 · Cited by 18
Continuous Glucose Monitoring: A Transformative Approach to the Detection of Prediabetes
Liu, X., & Zhang, J. (2024) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s493128 · Cited by 24
Metadata
- Authors
- American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., Khunti, K., Lingvay, I., Matfin, G., McCoy, R. G., Perry, M. L., Pilla, S. J., Polsky, S., Prahalad, P., Pratley, R. E., Segal, A. R., Seley, J. J., Selvin, E., Stanton, R. C., & Gabbay, R. A.
- ORCID
- ElSayed, Nuha A.
- Aleppo, Grazia
- Bannuru, Raveendhara R.
- Bruemmer, Dennis
- Collins, Billy S.
- Ekhlaspour, Laya
- Gaglia, Jason L.
- Hilliard, Marisa E.
- Johnson, Eric L.
- Khunti, Kamlesh
- Lingvay, Ildiko
- McCoy, Rozalina G.
- Perry, Mary Lou
- Pilla, Scott J.
- Polsky, Sarit
- Prahalad, Priya
- Pratley, Richard E.
- Segal, Alissa R.
- Seley, Jane Jeffrie
- Selvin, Elizabeth
- Stanton, Robert C.
- Gabbay, Robert A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2023-12-11
- Volume
- 47
- Issue
- Supplement_1
- Pages
- S20-S42
- ISSN
- 0149-5992 (ISSN-L)
- PMC
- PMC10725812
- OpenAlex
- W4389560718
- Cited by
- 2,086
- References
- 232
- Citations by year
- 2026: 771 · 2025: 903 · 2024: 408 · 2023: 1
- FWCI
- 74.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (K23DK121942)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- diabetes diagnosis, diabetes classification, diabetes mellitus, clinical guidelines, American Diabetes Association standards of care, quality of care
- MeSH terms
- Diabetes Mellitus, Endocrinology, Humans, Reference Standards, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.